The production of the vital drug Rivaroxaban, which reduces the risk of thrombosis, is fully localized in Russia.

Ensuring the uninterrupted availability of highly effective drugs for the prevention and treatment of thrombosis and other diseases of the cardiovascular system is the most important task of the pharmaceutical industry. Rivaroxaban is a priority drug for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism, its action is aimed at reducing the incidence of strokes, heart attacks, systemic thromboembolic complications and deaths caused by these diseases.

The properties of the active pharmaceutical substance (API) are a critically important parameter for ensuring the quality of a medicinal product. Technological parameters, such as the purity of the product, directly affect the stability of the dosage form and the safety of therapy. Promomed specialists have developed and implemented an optimized Rivaroxaban API production technology, which makes it possible to achieve the required quality parameters and increase the availability of the vital drug.

Alexander Rudko, Chief Operating Officer of JSC Biochemik, comments: "We continue our research activities aimed at developing innovative technologies for the synthesis of molecules and the production of substances, expand the range of products localized in a full cycle, and have all the necessary capacities for large-scale import substitution and meeting the needs of the state in essential drugs. The release of Rivaroxaban was a natural continuation of Promomed's systematic work to provide the country with modern medicines for the treatment of socially significant diseases."

Reducing dependence on foreign suppliers and the availability of a full production cycle are key aspects of the strategic development of the domestic pharmaceutical industry. Due to its own innovative chemical technologies and biotechnologies, as well as modern production facilities, Promomed is an active participant in the system of ensuring national drug safety and import independence of the country.

Promomed's priority is to develop new solutions for the creation of high-quality substances, regardless of the multi-stage synthesis and complexity of the technology, which makes it possible to improve the functional characteristics and achieve the highest quality of products.

1. https://ria.ru/